These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 17909198)

  • 1. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.
    Robenshtok E; Gafter-Gvili A; Goldberg E; Weinberger M; Yeshurun M; Leibovici L; Paul M
    J Clin Oncol; 2007 Dec; 25(34):5471-89. PubMed ID: 17909198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
    Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
    J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.
    Ethier MC; Science M; Beyene J; Briel M; Lehrnbecher T; Sung L
    Br J Cancer; 2012 May; 106(10):1626-37. PubMed ID: 22568999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
    Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
    BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal agents for preventing fungal infections in solid organ transplant recipients.
    Playford EG; Webster AC; Sorell TC; Craig JC
    Cochrane Database Syst Rev; 2004; (3):CD004291. PubMed ID: 15266524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.
    Playford EG; Webster AC; Sorrell TC; Craig JC
    J Antimicrob Chemother; 2006 Apr; 57(4):628-38. PubMed ID: 16459344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D; Depestel DD; Carver PL
    Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
    Wang JF; Xue Y; Zhu XB; Fan H
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Playford EG; Webster AC; Sorrell TC; Craig JC
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004920. PubMed ID: 16437504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
    Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
    Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
    Ping B; Zhu Y; Gao Y; Yue C; Wu B
    Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
    Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
    Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.